BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 8964866)

  • 1. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
    Cotterill AM; McKenna WJ; Brady AF; Sharland M; Elsawi M; Yamada M; Camacho-Hübner C; Kelnar CJ; Dunger DB; Patton MA; Savage MO
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up.
    MacFarlane CE; Brown DC; Johnston LB; Patton MA; Dunger DB; Savage MO; McKenna WJ; Kelnar CJ
    J Clin Endocrinol Metab; 2001 May; 86(5):1953-6. PubMed ID: 11344190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.
    Romano AA; Dana K; Bakker B; Davis DA; Hunold JJ; Jacobs J; Lippe B
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2338-44. PubMed ID: 19401366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH)-binding protein in prepubertal short children born small for gestational age: effects of growth hormone treatment. Swedish Study Group for Growth Hormone Treatment.
    Boguszewski M; Bjarnason R; Rosberg S; Carlsson LM; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1014-9. PubMed ID: 9100566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G; Baur F; Schweizer R; Ranke MB
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium-phosphate metabolism and bone markers in two patients with Noonan's syndrome treated with growth hormone].
    Praticò G; Palano GM; Lo Presti D; Parisi G; Caruso-Nicoletti M
    Minerva Pediatr; 2003 Dec; 55(6):593-8. PubMed ID: 14676730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group.
    Backeljauw PF; Underwood LE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.
    Zavras N; Meazza C; Pilotta A; Gertosio C; Pagani S; Tinelli C; Bozzola M
    Ital J Pediatr; 2015 Oct; 41():71. PubMed ID: 26444854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency.
    Shulman DI; Root AW; Diamond FB; Bercu BB; Martinez R; Boucek RJ
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4095-9. PubMed ID: 12970269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of growth deceleration after withdrawal of growth hormone therapy in idiopathic short stature.
    Lampit M; Hochberg Z
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3573-7. PubMed ID: 12161476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial.
    Noordam C; Van der Burgt I; Sengers RC; Delemarre-van de Waal HA; Otten BJ
    Acta Paediatr; 2001 Aug; 90(8):889-94. PubMed ID: 11529537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
    Binder G; Neuer K; Ranke MB; Wittekindt NE
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5377-81. PubMed ID: 15985475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
    Blum WF; Crowe BJ; Quigley CA; Jung H; Cao D; Ross JL; Braun L; Rappold G;
    J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency.
    Sas T; Mulder P; Hokken-Koelega A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3786-92. PubMed ID: 11061539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.